Cooper (COO) Q2 Deep Dive: The Inventory Reset and the Sale That Wasn't

Cooper reported a record second quarter and told investors two things would shape the rest of the year: it was deliberately cutting the inventory it ships for contact lenses, and it was weighing a sale of its fertility business, CooperSurgical. One quarter later the stock trades near $54, down about 15% on the latest report and roughly a third off its start to 2026. Both camps in June saw the same quarter and the same two plans. They disagreed only on what those plans were worth.

Shared facts, both camps sign this card. For the fiscal second quarter ended April 30, 2026, Cooper reported revenue of $1.082 billion, up 8% year over year and 5% organically, with non-GAAP earnings per share of $1.21, up 26%. It marked its tenth straight quarter above consensus. GAAP EPS was a loss of $0.40 because of a $271.6 million net charge tied to settling claims from the December 2023 embryo-culture-media recall, with more than 95% of claimants resolved. CooperVision, the lens business, grew 4% organically to $724 million while Asia-Pacific fell 6%, blamed on soft Japan and China demand and product rationalization. CooperSurgical grew 6% organically to $358 million, led by a 10% jump in fertility. Net debt stood at $2.3 billion, and for the year the company guided revenue of $4.285–4.321 billion, non-GAAP EPS of $4.58–4.66, and raised free cash flow to roughly $650 million. That is the record. The fight is over the two plans riding on top of it.

Round one: the inventory reset — discipline or slow demand? Management said an AI-enhanced inventory system was letting it reduce how much it ships into the channel. That is the accounting any shopper understands as the difference between sell-in and sell-through: Cooper's factory ships fewer lenses to retailers (some money comes later), even if consumers keep buying (the money still down the road) — or don't. The bull reads this as housekeeping. Cut production, bleed near-term growth and margin, get the channel clean and the cash flowing. The defense's own numbers support a version of that: third-quarter free cash flow jumped 66% to $273 million, and Cooper reaffirmed a target of more than $2.2 billion of cumulative free cash flow across fiscal 2026 to 2028 even after cutting its top-line guidance. Cash is real.

The bear's answer is that "inventory action" has become a two-quarter word for demand that is cooling, and the word keeps stretching. In the second quarter, Asia-Pacific was already down 6% because of Japan and China. By the third quarter, the picture darkened: CooperVision sales were flat at $717 million, Americas fell 2% organically, Asia-Pacific fell 5%, and management guided the fourth quarter's CooperVision organic growth to minus 2% to flat — outright decline — as the channel reset "normalizes." The scripted move was a foreseeable one-quarter hit. It has now been booked twice and is being reused for a third. When a management team keeps re-basing the floor lower under a "temporary" label, the label pays diminishing rent. Bull wins the cash-flow fact but the evidence margin by September belongs to the bear on the stock. Every cut to guidance since June has been a bear's point.

Round two: the sale that wasn't. The second pillar of the June story was optionality. With litigation largely settled, management said there was "robust interest" in CooperSurgical — from buyers of the whole business and of pieces — and that a deal could move "very quickly," with the vast majority of any proceeds headed to buybacks. That was a bull's catalyst: crystallize value, shrink the share count, fund it with a lender's cash.

Here the resolution cut against the bulls and the bears in different ways. When the third quarter landed, Cooper's board concluded the review and CooperSurgical, saying the offers received were not in shareholders' best interest. If you bought in June for the spin-off pop, that catalyst is gone, and the "sale optionality" premium in the stock evaporated — one reason for the 15% drop. But the same decision handed the bull a real counter. Rather than sell a growing fertility franchise at what management judged a weak point in the cycle, Cooper kept it and enlarged its repurchase authorization from $2 billion to $3 billion, buying back $339 million of stock in the third quarter alone at an average price near $69. A company that declines to sell, keeps a mid-single-digit grower, and uses its cash to buy back cheap shares is not a broken one. The bear's best answer to that is that buybacks into a falling earnings guide mean the denominator shrinks while the numerator keeps slipping — a way to dress up a declining number with capital return, not proof the business accelerates.

What $54 demands. Rebuild the market's math. At roughly $10 billion of market value on a mid-fiscal-year guide of about $4.53 in adjusted EPS, the stock sits near 12 times forward adjusted earnings — down by roughly a third from where it began the year and well under its trailing EV/EBITDA around 14. The price has stopped paying a premium for growth; it is now pricing continued softness at CooperVision and little credit for a CooperSurgical recovery. Reverse-engineered, the market is essentially saying the destocking is not one quarter deep, growth stays muted through 2027, and the buyback propping up per-share numbers does the heavy lifting. That is a pessimistic, but coherent, price — not an obviously wrong one, and not proof of a bargain. A beaten-down multiple is context, not a margin of safety; the bear's whole case rests on the guide falling again, and the bull's on it finally stopping.

Ruling. Bull on the business, bear on the stock — and the bear has been right on the stock so far, because the guide kept falling even as the tenth straight earnings beat was printed. Two quarters of escalating "inventory" language and a strategic review that closed without a sale are the exact things a June reader was told to watch, and both bent the wrong way. Today's price has largely refunded the June bull case, which is what makes this a genuine decision rather than a foregone one. The burden sits with the bull to show that sell-through was healthy underneath the sell-in cuts. That call flips at the fourth-quarter report, roughly December: if CooperVision's organic growth turns positive and full-year guidance stops sliding, the near-12-times multiple with a $3 billion buyback becomes the better odds. If the reset extends into fiscal 2027 and the guide falls a third time, the bear keeps the edge and today looks less like a floor than a step. The losing side's earliest signal to watch is simply which word management uses at the next report: "normalizing," or "again."